The research conducted on inhibitors of mutant BRAF in NSCLC is limited; however, extensive work has been done on elucidating mechanisms of resistance to BRAF inhibitors in melanoma and may provide parallels to mechanisms in lung cancer. This evidence concerns the gene BRAF and lung cancer.